{"entity":{"id":"nicola-gokbuget","kind":"person","name":"Nicola Gökbuget","aka":[],"tldr":"Leads the German GMALL group and showed blinatumomab clears residual leukaemia in adults with ALL.","summary":"Nicola Gökbuget leads the German Multicenter Study Group for Adult ALL (GMALL), whose trials defined risk-adapted therapy and MRD-guided treatment in adult ALL, and was principal investigator of the BLAST trial showing blinatumomab converts most MRD-positive patients to MRD-negative with improved survival, the basis for its MRD indication. She co-authored the European guidelines on adult ALL.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gokbuget%20N%5BAuthor%5D%20acute%20lymphoblastic%20leukemia"}],"tags":["all","mrd","cooperative-group"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":["mrd-testing","t-cell-engager"],"targets":["cd19"],"drugs":["blinatumomab"],"companies":[],"institutions":["uct-frankfurt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-e1910-blinatumomab-mrd-negative-all-nejm-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the GMALL Study Group; Professor of Medicine, University Hospital Frankfurt","institutionId":"uct-frankfurt","specialisms":["Adult acute lymphoblastic leukaemia","Measurable residual disease","Cooperative-group trials","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gokbuget%20N%5BAuthor%5D%20acute%20lymphoblastic%20leukemia"}],"papers":[{"title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia (BLAST)","journal":"Blood","year":2018,"doi":"10.1182/blood-2017-08-798322"},{"title":"Adult acute lymphoblastic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","journal":"Annals of Oncology","year":2016,"doi":"10.1093/annonc/mdw025"},{"title":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312948","doi":"10.1056/NEJMoa2312948"}]},"route":"/people/nicola-gokbuget/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"institution":[{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/"}],"paper":[{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/"}]}}